search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Antimicrobial resistance


Call for action on sepsis and AMR


Dr. Ron Daniels BEM, Founder and Chief Medical Officer, UK Sepsis Trust warns we cannot afford to wait for an infection to become sepsis before we take it seriously.


I have spent much of my career looking after people at their sickest. I have seen patients arrive in intensive care with an infection that, only hours earlier, may have seemed relatively ordinary. One of the most important things I have learned about sepsis is that it does not always start by looking serious. The most common starting point is the lungs. Sometimes it is the abdomen. And sometimes it is something as familiar as a urinary tract infection (UTI). By the time someone has developed sepsis,


the conversation is no longer simply about treating an infection. We are trying to prevent organ failure, prolonged illness and, in the worst cases, death. But by then, we are often dealing with the consequences of decisions made much earlier.


Tackling two connected issues Following on from Infection Prevention Week, last month, and as we approach World Antimicrobial Resistance (AMR) Awareness Week, taking place in November, we have an opportunity to connect two conversations that are too often held separately: preventing sepsis and tackling antimicrobial resistance. Sepsis and AMR can sound like problems


for Intensive Care Units and microbiology laboratories. However, both can begin with something as ordinary as a UTI, and what happens at the beginning of that infection can influence what happens further along the pathway. UTIs are among the most common infections we see. Around half of women will experience at least one in their lifetime, and many will have repeat infections. They are also the most common type of bacterial infection in people aged 65 and over. Despite being so familiar to so many, though, sometimes something as


seemingly benign as a UTI can trigger life- threatening sepsis. So, the important question is not simply whether a patient has a UTI. It is whether we have identified the infection accurately, early enough, and with enough useful information to treat it effectively. The quality of a diagnosis, however, depends on the quality of the information behind it. Take UTIs. In primary care, their diagnosis still leans heavily on the urine dipstick. It is quick and convenient, but it has important limitations. Dipsticks can miss as many as 45–50% of UTIs, meaning that a negative result does not necessarily rule out infection. The reliability of these diagnostic results also


depends on the quality of the specimen. Patients are often asked to collect their own sample, sometimes at home, without clear guidance on how to obtain a good-quality specimen or why this matters. Yet that sample can shape the next steps in the clinical pathway, influencing both the diagnosis and the treatment decisions that


The important question is not simply whether a patient has a UTI. It is whether we have identified the infection accurately, early enough, and with enough useful information to treat it effectively.


32 www.clinicalservicesjournal.com I November 2026


follow. That is why ensuring a clean midstream sample and minimising contamination is an important part of getting that information right, and devices designed for midstream collection together with clear patient guidance can help support this.


A UTI that is not diagnosed, diagnosed


inaccurately or diagnosed too slowly may go untreated. Even when diagnosed, without accurate sampling it is more difficult to be certain that the patient is receiving the right antibiotic. The infection may not clear. Symptoms persist or return, and the patient needs further consultations and potentially further courses of antibiotics. This is where antimicrobial resistance enters the picture. When an infection is not treated effectively, it can persist or return, leaving the patient needing further treatment and potentially further courses of antibiotics. Over time, this repeated exposure can increase the risk of resistant bacteria, making future infections harder to treat and leaving fewer effective antibiotics available. And the pathway does not stop there. An infection that is not successfully treated can, in some cases, progress to become a more complex or deep-seated infection which is more likely to lead to sepsis.


Zerbor - stock.adobe.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71